Greg Sadowski named Senior VP, Client Services; Kathleen A. Walsh named VP, Product Management; Gilbert V. Molina named Director, Corporate Systems
Completes leadership for team to commercialize and support initial
application of NewCardio's platform technology
SANTA CLARA, Calif., Oct. 17 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced the hiring of three key executives to complete the Company's client services team. Greg Sadowski joined NewCardio as Senior Vice President, Client Services. Kathleen A. Walsh joined as Vice President, Product Management. Gilbert V. Molina joined as Director, Corporate Systems.
Mr. Sadowski brings 11 years experience in the Clinical Research sector and a proven track record in rapidly creating new functional groups, business units and technical architectures from the ground up. He joins NewCardio from eResearchTechnology (eRT), where he most recently served on the Executive Management Team as Senior VP of eRT's new Electronic Patient Reported Outcomes (ePRO) business unit while retaining responsibilities as the company's senior executive for the Information Technology and Customer Care groups. Mr. Sadowski will be responsible for effectively preparing, delivering and supporting the NewCardio cardiovascular diagnostic technology solutions, to include the Professional Services, Information Technology, Customer Care and Quality Assurance groups.
Mrs. Walsh also joins NewCardio from eRT, bringing over 11 years of Corelab Management experience. As Vice-President, Project Management she was responsible for leading the Global Project Management department, the Online Reporting Services department and the Training Academy department. She was specifically responsible for developing, implementing and streamlining processes to maximize revenue while maintaining and enhancing client satisfaction. At NewCardio, Mrs. Walsh will be responsible for Product Management, working with both internal and external teams to effectively define and deliver the strategic cardiovascular diagnostic technology solutions that will be derived from the NewCardio 3Dimensional platform technology.
Mr. Molina is a proven IT manager with nine years experience working at diverse, fast-paced and rapidly-growing organizations. He brings a track record of working with diverse groups and managing complex, mission-critical projects. Most recently, he served as Manager, Information Technology where he oversaw IT Operations at eRT's headquarters. At NewCardio he will be responsible for developing and supporting the IT infrastructure, to include hardware, networks and corporate systems, required to support the strategic growth initiatives of the company.
Vincent Renz, NewCardio's President, commented, "I have worked closely with each of these three professionals and as such, have great respect for their capabilities and expertise in working together as a team to bring quality solutions to market. I'm excited to have them join NewCardio, providing a solid foundation for building a world class Client Services organization focused on working together for our customers. This represents a milestone event for NewCardio, as not only will this team prove instrumental in accelerating our commercialization efforts, but will also send a clear signal to our potential customers across the life sciences and health care industries of our commitment to providing stellar service and compelling value."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit http://www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
|SOURCE NewCardio, Inc.|
Copyright©2008 PR Newswire.
All rights reserved